ALXO — ALX Oncology Holdings Balance Sheet
0.000.00%
- $80.33m
- $13.24m
- 25
- 33
- 74
- 39
Annual balance sheet for ALX Oncology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 434 | 364 | 266 | 183 | 128 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | — | 1 | 1 | 1.34 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 436 | 367 | 271 | 189 | 134 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.052 | 3.4 | 9.79 | 10.8 | 9.63 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 436 | 380 | 306 | 243 | 148 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.2 | 15.3 | 28.3 | 36 | 18.5 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.21 | 17.1 | 43 | 52.8 | 34.2 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 430 | 363 | 263 | 190 | 114 |
| Total Liabilities & Shareholders' Equity | 436 | 380 | 306 | 243 | 148 |
| Total Common Shares Outstanding |